Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

pharma alliance

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

- PMLiVE

FDA clears Jardiance combo for type 2 diabetes

Combination treatment Synjardy is fifth drug to come from Boehringer/Lilly diabetes alliance

- PMLiVE

Lilly and Boehringer launch Lantus biosimilar in UK

Competition in the insulin drug market begins to heat up

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

- PMLiVE

Boehringer COPD drug ‘could give patients more independence’

New data shows Stiolto improves patients’ lives

- PMLiVE

Boehringer returns to growth in first half

German firm back on track after a tough sales period

- PMLiVE

Hikma pays $2.6bn for Boehringer’s US generics unit

Follows Teva’s $40.5bn purchase of Allgeran’s generics business earlier this week

- PMLiVE

Boehringer plans new filings for Giotrif in lung cancer

Firm to file drug for squamous cell carcinoma of the lung

- PMLiVE

Boehringer’s ASCO blog picks up digital excellence award

Work by Ogilvy HealthPRwins Prescription Products/Patient Health prize

- PMLiVE

Boehringer’s Spiriva combo approved in first EU markets

Combination therapy available countries including the UK, Ireland and Spain

- PMLiVE

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links